3P Biopharmaceuticals renews its “Credit Impôt Recherche” (CIR) by the French Ministry of Higher Education and Research

3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.

3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.

The CIR “Credit Impôt Recherche” or French Research Tax Credit is a corporate tax relief measure that allows French companies to declare innovative research costs and obtain a significant reduction on their tax bill.

This renewal allows 3P’s French customers the opportunity to receive an important percentage of their R&D costs in tax credits. Therefore, 3P Biopharmaceuticals continues to bring added-value to their French clients thanks to this opportunity to increase the quality, safety and efficacy of their biologic drugs.

3P Biopharmaceuticals already counts with a strong French client portfolio at different stages of their biologics development who have embraced this interesting incentive over the last years.

3P Biopharmaceuticals successfully extends its French CIR certificate for 2020-2024.

As 3P Biopharmaceuticals CEO Dámaso Molero explains: “It is wonderful news to renew CIR certificate for another four years to confirm 3P Biopharmaceuticals, once again, as a valuable and competitive CDMO partner for French biotech and pharma companies interested in developing biologics.

3P Biopharmaceuticals once again demonstrates its capacity to carry out processes development and manufacturing of molecules developed within diverse therapeutic applications. At the same time, 3P Biopharmaceuticals consolidates a competitive position among the most esteemed CDMOs in Europe.

Our dedicated team of specialists will be happy to discuss any of your CDMO needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

BrainEver and 3P Biopharmaceuticals collaborate on development of recombinant human homeoprotein Engrailed-1

Published: 15th November 2022
3P Bio will focus on the transfer of the production process as well as the cGMP manufacturing of the drug substance to be used in Phase I and II clinical trials. The novel drug could cure neurodegenerative diseases such as Amyotrophic Lateral Sclerosis.
Read more

3P Biopharmaceuticals awards the prize for the best Master’s Thesis (TFM)

Published: 3rd October 2022
At the closing of the fifth edition of the Master in Galenic Design and Manufacturing in the Pharmaceutical Industry of the University of Navarra.
Read more

3P Biopharmaceuticals among the 100 best companies to work for in Spain

Published: 27th September 2022
The prestigious ranking is based on an exhaustive questionnaire that Actualidad Económica prepares and publishes every year, and which seeks to evaluate and reward those companies whose human resources management makes them benchmarks.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.